Evaluation of the effectiveness of X-ray protective aprons in experimental and practical fields

Few practical evaluation studies have been conducted on X-ray protective aprons in workplaces. We examined the effects of exchanging the protective apron type with regard to exposure reduction in experimental and practical fields, and discuss the effectiveness of X-ray protective aprons. Experimental field evaluations were performed by the measurement of the X-ray transmission rates of protective aprons. Practical field evaluations were performed by the estimation of the differences in the transit doses before and after the apron exchange. A 0.50-mm lead-equivalent-thick non-lead apron had the lowest transmission rate among the 7 protective aprons, but weighed 10.9 kg and was too heavy. The 0.25 and 0.35-mm lead-equivalent-thick non-lead aprons differed little in the practical field of interventional radiology. The 0.35-mm lead apron had lower X-ray transmission rates and transit doses than the 0.25-mm lead-equivalent-thick non-lead apron, and each of these differences exceeded 8 % in the experimental field and approximately 0.15 mSv/month in the practical field of computed tomography (p < 0.01). Therefore, we concluded that the 0.25-mm lead-equivalent-thick aprons and 0.35-mm lead apron are effective for interventional radiology operators and computed tomography nurses, respectively

Evaluation of the effectiveness of X-ray protective aprons in experimental and practical fields

Few practical evaluation studies have been conducted on X-ray protective aprons in workplaces. We examined the effects of exchanging the protective apron type with regard to exposure reduction in experimental and practical fields, and discuss the effectiveness of X-ray protective aprons. Experimental field evaluations were performed by the measurement of the X-ray transmission rates of protective aprons. Practical field evaluations were performed by the estimation of the differences in the transit doses before and after the apron exchange. A 0.50-mm lead-equivalent-thick non-lead apron had the lowest transmission rate among the 7 protective aprons, but weighed 10.9 kg and was too heavy. The 0.25 and 0.35-mm lead-equivalent-thick non-lead aprons differed little in the practical field of interventional radiology. The 0.35-mm lead apron had lower X-ray transmission rates and transit doses than the 0.25-mm lead-equivalent- thick non-lead apron, and each of these differences exceeded 8% in the experimental field and approximately 0.15 mSv/month in the practical field of computed tomography (p <0.01). Therefore, we concluded that the 0.25-mm lead-equivalent-thick aprons and 0.35-mm lead apron are effective for interventional radiology operators and computed tomography nurses, respectively. © The Author(s) 2013

A novel removable shield attached to C-arm units against scattered X-rays from a patient\u27s side

Objectives We invented a drape-like shield against scattered X-rays that can safely come into contact with medical equipment or people during fluoroscopically guided procedures. The shield can be easily removed from a C-arm unit using one hand. We evaluated the use of the novel removable shield during the endoscopic retrograde cholangiopancreatography (ERCP) procedure. Methods We measured the dose rate of scattered X-rays around endoscopists with and without this removable shield and surveyed the occupational doses to the ERCP staff. We also examined the endurance of the shield. Results The removable shield reduced the dose rate of scattered X-rays to one-tenth and reduced the monthly dose to an endoscopist by at least two-fifths. For 2.5 years, there was no damage to the shield and no loosening of the seam. The bonding of the hook-and-loop fasteners did not weaken, although the powerful double-sided tapes made especially for plastic did. Conclusions The removable shield can reduce radiation exposure to the ERCP staff and may contribute to reducing the exposure to the eye lenses of operators. It would also be possible to expand its use to other fluoroscopically guided procedures besides ERCP because it is a light, simple, and useful device. Key Points • We invented a shield that can be removed from C-arm units with one hand.• The removable shield reduces the dose rate of X-rays to one-tenth.• The removable shield reduces operator exposure by two-fifths.• The removable shield is durable, lasting for several years.• The drape-like removable shield is light, simple, and useful. © 2014 European Society of Radiology

Clinico-pathological analysis referring hemeoxygenase-1 in acute fibrinous and organizing pneumonia patients

AbstractAcute fibrinous and organizing pneumonia (AFOP) is a very rare pathological entity of lung injury characterized by intra-alveolar fibrin balls.Hemeoxygenase (HO) -1 is a cytoprotective enzyme against oxidative stress and inflammation. It is known to be expressed in the alveolar macrophages in the healthy adults and overexpressed in other various lung cells of the lung injury patients.We experienced two cases of subacute form AFOP for these 10 years and reviewed clinico-pathological characteristics. The average age was 62 years old and both were male. The etiology of both cases was idiopathic. The average PaO2/FIO2 ratio was 274.5 ± 84.1. The average levels of C-reactive protein and surfactant protein - A of the serum were elevated to 19.8 ± 6.3 mg/dL and 67.6 ± 15.8 ng/mL, respectively. Serum sialylated carbohydrate antigen levels were normal in both cases. The characteristic radiographic findings were bilateral consolidations and ground glass opacities. Lung biopsy specimens revealed fibrin balls and alveolitis with abundant cellular HO-1 expression. Steroid response was excellent and the pulmonary involvements absolutely disappeared for about 3 months

Experimental model for the irradiation-mediated abscopal effect and factors influencing this effect

Radiotherapy (RT) is the primary treatment for cancer. Ionizing radiation from RT induces tumor damage at the irradiated site, and, although clinically infrequent, may cause regression of tumors distant from the irradiated site-a phenomenon known as the abscopal effect. Recently, the abscopal effect has been related to prolongation of overall survival time in cancer patients, though the factors that influence the abscopal effect are not well understood. The aim of this study is to clarify the factors influencing on abscopal effect. Here, we established a mouse model in which we induced the abscopal effect. We injected MC38 (mouse colon adenocarcinoma) cells subcutaneously into C57BL/6 mice at two sites. Only one tumor was irradiated and the sizes of both tumors were measured over time. The non-irradiated-site tumor showed regression, demonstrating the abscopal effect. This effect was enhanced by an increase in the irradiated-tumor volume and by administration of anti-PD1 antibody. When the abscopal effect was induced by a combination of RT and anti-PD1 antibody, it was also influenced by radiation dose and irradiated-tumor volume. These phenomena were also verified in other cell line, B16F10 cells (mouse melanoma cells). These findings provide further evidence of the mechanism for, and factors that influence, the abscopal effect in RT

Evidence for phosphorylation of rat liver glucose-regulated protein 58, GRP58/ERp57/ER-60, induced by fasting and leptin

AbstractGlucose-regulated protein 58 (GRP58)-like immunoreactivity in rat liver obtained in the evening or after fasting underwent an electrophoretic band-shift, which disappeared after phosphatase-treatment. Since mass spectrometric analysis raised a possibility that Ser150 of GRP58 is phosphorylated, an antibody against the phosphoserine150 GRP58 was generated. Immunoreactivity to this antibody was increased in the evening and after fasting. Since GRP58 was shown to interact with signal transducer and activator of transduction 3 (STAT3), a leptin-related protein, the effect of leptin was examined. Immunoreactivity to the anti-phosphoGRP58 antibody was markedly elevated after the leptin injection, indicating that Ser150 of GRP58 is phosphorylated after fasting and leptin-treatment

Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma

Background: Esophageal squamous cell carcinoma (ESCC) is one of the most intractable cancers, so the development of novel therapeutics has been required to improve patient outcomes. Curcumin, a polyphenol from Curcuma longa, exhibits various health benefits including antitumor effects, but its clinical utility is limited because of low bioavailability. Theracurmin® (THC) is a highly bioavailable curcumin dispersed with colloidal submicron particles. Methods: We examined antitumor effects of THC on ESCC cells by cell viability assay, colony and spheroid formation assay, and xenograft models. To reveal its mechanisms, we investigated the levels of reactive oxygen species (ROS) and performed microarray gene expression analysis. According to those analyses, we focused on NQO1, which involved in the removal of ROS, and examined the effects of NQO1-knockdown or overexpression on THC treatment. Moreover, the therapeutic effect of THC and NQO1 inhibitor on ESCC patient-derived xenografts (PDX) was investigated. Results: THC caused cytotoxicity in ESCC cells, and suppressed the growth of xenografted tumors more efficiently than curcumin. THC increased ROS levels and activated the NRF2–NMRAL2P–NQO1 expressions. Inhibition of NQO1 in ESCC cells by shRNA or NQO1 inhibitor resulted in an increased sensitivity of cells to THC, whereas overexpression of NQO1 antagonized it. Notably, NQO1 inhibitor significantly enhanced the antitumor effects of THC in ESCC PDX tumors. Conclusions: These findings suggest the potential usefulness of THC and its combination with NQO1 inhibitor as a therapeutic option for ESCC

Nationwide survey of radiation exposure during pediatric computed tomography examinations and proposal of age-based diagnostic reference levels for Japan

Background: Diagnostic reference levels (DRLs) have not been established in Japan. Objective: To propose DRLs for CT of the head, chest and abdomen for three pediatric age groups. Materials and methods: We sent a nationwide questionnaire by post to 339 facilities. Questions focused on pediatric CT technology, exposure parameters, CT protocols, and radiation doses for age groups <1 year, 1-5 years, and 6-10 years. Results: For the three age groups in the 196 facilities that responded, the 75th percentile values of volume CT dose index based on a 16-cm phantom (CTDIvol 16 [mGy]) for head, chest and abdominal CT were for infants 39.1, 11.1 and 12.0, respectively; for 1-to 5-year-olds 46.9, 14.3 and 16.7, respectively; and for 6-to 10-year-olds 67.7, 15.0 and 17.0, respectively. The corresponding dose–length products (DLP 16 [mGy・cm]) for head, chest and abdominal CT were for infants 526.1, 209.1 and 261.5, respectively; for 1-to 5-year-olds 665.5, 296.0 and 430.8, respectively; and for 6-to 10-year-olds 847.9, 413.0 and 532.2, respectively. Conclusion: The majority of CTDIvol 16 and DLP 16 values for the head were higher than DRLs reported from other countries. For risk reduction, it is necessary to establish DRLs for pediatric CT in Japan. © 2015 Springer-Verlag Berlin HeidelbergEmbargo Period 12 month

HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function

Clinical cancer genome sequencing detects oncogenic variants that are potential targets for cancer treatment, but it also detects variants of unknown significance. These variants may interact with each other to influence tumor pathophysiology, however, such interactions have not been fully elucidated. Additionally, the effect of target therapy for those variants also unclarified. In this study, we investigated the biological functions of a HER2 mutation (G776S mutation) of unknown pathological significance, which was detected together with APC mutation by cancer genome sequencing of samples from a colorectal cancer (CRC) patient. Transfection of the HER2 G776S mutation alone slightly increased the kinase activity and phosphorylation of HER2 protein, but did not activate HER2 downstream signaling or alter the cell phenotype. On the other hand, the HER2 G776S mutation was shown to have strong oncogenic potential when loss of APC function was accompanied. We revealed that loss of APC function increased Wnt pathway activity but also increased RAS-GTP, which increased ERK phosphorylation triggered by HER2 G776S transfection. In addition, afatinib, a pan-HER tyrosine kinase inhibitor, suppressed tumor growth in xenografts derived from HER2 G776S-transfected CRC cells. These findings suggest that this HER2 mutation in CRC may be a potential therapeutic target